TY - JOUR
T1 - Sleep problems in fragile X syndrome
T2 - Cross-sectional analysis of a large clinic-based cohort
AU - for the FORWARD Consortium
AU - Budimirovic, Dejan B.
AU - Protic, Dragana D.
AU - Delahunty, Carol M.
AU - Andrews, Howard F.
AU - Choo, Tse Hwei
AU - Xu, Qing
AU - Berry-Kravis, Elizabeth
AU - Kaufmann, Walter E.
N1 - Funding Information:
Work on this publication was supported by cooperative agreements #U01DD000231, #U19DD000753, and # U01DD001189, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Department of Health and Human Services. We would like to thank everyone involved in FORWARD: patients, their families, and team of FORWARD researchers. We particularly acknowledge Hannah Jackson's contribution, who assisted with the data preparation and completed multiple initial analysis, helped with sections of the manuscript, including relevant most recent references.
Funding Information:
Work on this publication was supported by cooperative agreements #U01DD000231, #U19DD000753, and # U01DD001189, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Department of Health and Human Services. We would like to thank everyone involved in FORWARD: patients, their families, and team of FORWARD researchers. We particularly acknowledge Hannah Jackson's contribution, who assisted with the data preparation and completed multiple initial analysis, helped with sections of the manuscript, including relevant most recent references.
Funding Information:
Dejan B. Budimirovic has received funding from Seaside, Roche, Neuren, Pfizer, Shire, Lundbeck, Forest, Sunovion, SyneuRX, Alcobra, Akili, Medgenics, Purdue, Supernus as a main sub‐investigator, and from Ovid and Zynerba Pharmaceuticals as a principal investigator on clinical trials. He also consulted on clinical trial outcome measures (Seaside, Ovid). All the above funding has been directed to Kennedy Krieger Institute/the Johns Hopkins Medical Institutions; Dejan B. Budimirovic receives no personal funds and the Institute has no relevant financial interest in any of the commercial entities listed. Elizabeth Berry‐Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, BioMarin, Cydan, Fulcrum, GeneTx, GW, Ionis, Lumos, Marinus, Neuren, Neurotrope, Novartis, Ovid, Roche, Seaside Therapeutics, Ultragenyx, Vtesse/Sucampo/Mallinckrodt, Yamo, and Zynerba Pharmaceuticals to consult on clinical trial design, run clinical trials, or develop testing standards or biomarkers, all of which is directed to RUMC in support of rare disease programs; Elizabeth Berry‐Kravis receives no personal funds, and RUMC has no relevant financial interest in any of the commercial entities listed. Walter E. Kaufmann is Chief Medical Officer of Anavex Life Sciences Corporation. He has been a consultant to AveXis, EryDel, GW, Marinus, Neuren, Newron, Ovid, Stalicla, and Zynerba. Currently, WEK does not receive personal funds and has no financial interest in any of these commercial entities. The other co‐authors declare that they have no competing interests.
Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2022/4
Y1 - 2022/4
N2 - Fragile X syndrome (FXS), the leading cause of inherited intellectual disability and autism spectrum disorder, is associated with multiple neurobehavioral abnormalities including sleep difficulties. Nonetheless, frequency, severity, and consequences of sleep problems are still unclear. The Fragile X Online Registry with Accessible Research Database (FORWARD-version-3), including Clinician Report and Parent Report forms, was analyzed for frequency, severity, relationship with behavioral problems, and impact of sleep difficulties in a mainly pediatric cohort. A focused evaluation of sleep apnea was also conducted. Six surveyed sleep difficulties were moderately frequent (~23%–46%), relatively mild, affected predominantly younger males, and considered a problem for 7%–20% of families. Snoring was more prevalent in older individuals. All sleep difficulties were associated with irritability/aggression and most also to hyperactivity. Only severe snoring was correlated with sleep apnea (loud snoring: 30%; sleep apnea: 2%–3%). Sleep difficulties are prevalent in children with FXS and, although they tend to be mild, they are associated with behavioral problems and negative impact to families. Because of its cross-sectional nature, clinic-origin, use of ad hoc data collection forms, and lack of treatment data, the present study should be considered foundational for future research aiming at better recognition and management of sleep problems in FXS.
AB - Fragile X syndrome (FXS), the leading cause of inherited intellectual disability and autism spectrum disorder, is associated with multiple neurobehavioral abnormalities including sleep difficulties. Nonetheless, frequency, severity, and consequences of sleep problems are still unclear. The Fragile X Online Registry with Accessible Research Database (FORWARD-version-3), including Clinician Report and Parent Report forms, was analyzed for frequency, severity, relationship with behavioral problems, and impact of sleep difficulties in a mainly pediatric cohort. A focused evaluation of sleep apnea was also conducted. Six surveyed sleep difficulties were moderately frequent (~23%–46%), relatively mild, affected predominantly younger males, and considered a problem for 7%–20% of families. Snoring was more prevalent in older individuals. All sleep difficulties were associated with irritability/aggression and most also to hyperactivity. Only severe snoring was correlated with sleep apnea (loud snoring: 30%; sleep apnea: 2%–3%). Sleep difficulties are prevalent in children with FXS and, although they tend to be mild, they are associated with behavioral problems and negative impact to families. Because of its cross-sectional nature, clinic-origin, use of ad hoc data collection forms, and lack of treatment data, the present study should be considered foundational for future research aiming at better recognition and management of sleep problems in FXS.
KW - fragile X syndrome
KW - insomnia
KW - problem behaviors
KW - quality of life
KW - sleep apnea
UR - http://www.scopus.com/inward/record.url?scp=85120956431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120956431&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.62601
DO - 10.1002/ajmg.a.62601
M3 - Article
C2 - 34889523
AN - SCOPUS:85120956431
SN - 1552-4825
VL - 188
SP - 1029
EP - 1039
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 4
ER -